Pipeline
EU501 (HER2 x 4-1BB)
| Indication HER2 positive solid cancer | Target /Drug class Anti-human 4-1BB/HER2 mBsAb | Development Stage Non-clinical |
Summary
- Tumor cell-specific killing effect – low side effects
- Better efficacy for tumor clearance than monospecific antibody
